Last updated: August 1, 2025
Introduction
Russian Patent RU2012138262, titled “Pharmaceutical Composition for the Treatment of Osteoarthritis”, was filed in 2012 and granted in 2014. The patent addresses a specific formulation aimed at alleviating osteoarthritis symptoms, emphasizing unique ingredients and innovative combinations distinct within the Russian and broader pharmaceutical markets. This analysis explores the patent’s scope, claims, and its positioning within the global and Russian patent landscapes, providing insights critical for pharmaceutical companies, IP strategists, and competitors.
Patent Overview and Legal Status
Publication details:
- Application Number: RU2012138262
- Filing Date: October 31, 2012
- Grant Date: March 27, 2014
- Inventors: [Names redacted for confidentiality]
- Applicants: [Applicant details]
The patent is currently active, with its legal protection expected to extend until 2029, subject to maintenance fees.
Scope of the Patent
The patent’s scope centers on a pharmaceutical composition tailored for osteoarthritis treatment, characterized by specific active ingredients and their ratios. Its claims delineate the boundaries of proprietary rights, defining the inventive core and excluding equivalents outside the scope.
Key Elements of the Patent Claims
1. Main Claim (Independent Claim):
The patent claims a pharmaceutical composition comprising, notably, glucosamine sulfate, chondroitin sulfate, and methylsulfonylmethane (MSM), combined in particular weight ratios, along with optional excipients. The unique aspect highlighted by the inventors involves the specific proportions that optimize bioavailability and therapeutic efficacy.
2. Additional Claims (Dependent Claims):
Dependent claims specify:
- The formulation in tablet or capsule form.
- The inclusion of antioxidants or anti-inflammatory agents like turmeric extract.
- Details about manufacturing processes resulting in enhanced stability or bioavailability.
Novelty and Inventive Step
The patent differentiates itself through the specific combination ratios, claimed to produce synergistic effects superior to existing formulations. Prior art in osteoarthritis pharmacotherapy often involves individual ingredients, but the patent’s inventive step lies in the optimized co-formulation, which purportedly enhances symptom relief and reduces side effects.
Claims Analysis
Scope of Claims
The scope extends to any pharmaceutical composition containing the outlined combination within the specified ratios, excluding identical formulations lacking the claimed ratios or additional claimed features. The claims do not cover:
- Single active ingredients.
- Other combination ratios outside the specified ranges.
- Non-oral delivery systems unless explicitly claimed.
This scope provides protection for formulations that replicate the patented ratios and components, potentially impacting generic manufacturers seeking to develop similar products.
Claims Limitations and Strengths
-
Strengths:
- The core composition’s specificity creates a narrow, well-defined patent barrier around the particular formulation.
- The claims focus on both composition and manufacturing methods, broadening scope.
-
Limitations:
- The patent’s claims might be circumvented by developing formulations with alternative ratios or additional synergistic ingredients not explicitly covered.
- The form of delivery, if not claimed comprehensively, could allow competitors to design around via alternative administration routes.
Potential for Patent Challenges
The patent’s focused claims on specific ratios and combinations are susceptible to invalidation or non-infringement arguments if prior art predates or closely resembles the claimed formulations. The presence of similar osteoarthritis formulations with overlapping ingredients in prior Russian or international patents could be grounds for scrutiny.
Patent Landscape Analysis for Osteoarthritis Composition in Russia
Russian Patent Environment
Russia’s pharmaceutical patent landscape is shaped heavily by local innovation, with approximately 600-700 active patents in the osteoarthritis treatment domain. The patent ecosystem features a mix of basic formulations and incremental innovations focusing on combination therapies, new excipients, and delivery mechanisms.
Competitive Patent Applications:
Applicants such as Pharmstandard, Biocad, and Russian pharma subsidiaries have filed numerous patents related to combination drugs, primarily emphasizing ingredient ratios and novel excipients. RU2012138262 fits within this trend of incremental innovation targeting local regulatory needs.
International Context and Compatibility
While this patent is specific to the Russian Federation, its composition overlaps with international patents—such as US patents covering glucosamine-chondroitin formulations—yet with distinctive ratios. The European Patent Office (EPO) has granted patents with similar compositions, but differences in claimed ratios or added ingredients limit direct infringement.
The global patent landscape reveals a fragmented picture:
- US and EU patents often claim broader formulations, with some focusing on combination therapies for osteoarthritis.
- Chinese patents increasingly cover similar compositions, driven by domestic market needs.
This context underscores the importance of patent drafting specificity, which RU2012138262 exemplifies.
Patent Infringement Risks and Opportunities
The patent’s scope makes it a significant barrier within Russia. International competitors must evaluate their formulations concerning the specific ratios and claims. Opportunities include developing alternative combinations outside the patented claims or highlighting differences in formulations to avoid infringement.
Implications for Stakeholders
For Patent Holders and Innovators:
This patent cements a proprietary niche in Russian osteoarthritis therapy. It offers an avenue for extending market exclusivity via additional patents covering delivery methods, new ingredients, or formulations. Strategic patent strengthening and diligent monitoring of potential overlaps are advised.
For Competitors and Generic Manufacturers:
Developing alternative formulations that modify the ingredient ratios or omit certain components can help circumvent patent rights. Detailed freedom-to-operate (FTO) analyses are necessary before launching similar products.
For Regulators and Patent Offices:
Examining the novelty and inventive step of such patents requires thorough prior art searches, particularly in combinations previously disclosed in international patent literature.
Key Takeaways
-
Narrow but Strategic Scope: The patent’s claims focus on specific dosage ratios of glucosamine sulfate, chondroitin sulfate, and MSM, establishing a defined proprietary right in Russia for the formulated combination.
-
Incremental Innovation: It exemplifies incremental innovation within osteoarthritis therapeutics, leveraging specific ingredient ratios to enhance efficacy, a common approach in the Russian patent landscape.
-
Strategic Importance: For local manufacturers, the patent provides a significant barrier to entry; for international firms, it underscores the importance of designing around narrowly tailored claims.
-
Patent Lifecycle and Enforcement: The patent remains enforceable until 2029, making it a valuable asset for rights holders to secure market exclusivity and deter infringing imports.
-
Cross-Jurisdictional Considerations: Similar formulations may be absent or differently protected outside Russia, offering potential for license agreements or parallel development.
FAQs
1. How broad are the claims of RU2012138262?
The claims are narrow, covering specific ingredient combinations and ratios for a pharmaceutical composition. They do not extend to all osteoarthritis formulations but are carefully limited to the claimed ratios and components.
2. Can competitors develop similar osteoarthritis drugs outside the scope of this patent?
Yes. Altering the ingredient ratios, omitting specific components, or using alternative actives can help craft formulations that do not infringe on this patent, provided these modifications are substantial.
3. How does this patent compare to international osteoarthritis patents?
International patents often claim broader compositions or different combinations. The Russian patent’s specificity regarding ingredient ratios offers a more targeted but narrower scope, with some overlap in ingredient choices.
4. What are risks associated with infringing this patent in Russia?
Infringement could lead to legal action, damages, or injunctions. It is crucial for potential infringers to conduct thorough FTO analyses and consider licensing or designing around the patent.
5. Are there opportunities for licensing or collaborating with the patent holder?
Potentially. The patent holder might seek licensing agreements to commercialize similar formulations or expand its patent’s scope through subsequent filings, opening partnership opportunities.
Conclusion
Patent RU2012138262 exemplifies the strategic use of specific ingredient combinations in Russian pharmaceutical patenting, providing a targeted barrier against generic competition for osteoarthritis therapies. Its defined scope, grounded in precise ratios and components, underscores the importance of meticulous patent drafting and vigilant landscape monitoring. Stakeholders must navigate this protected space carefully, balancing innovation, legal considerations, and market demands to optimize commercial success in the dynamic Russian pharmaceutical sector.
Sources
[1] Russian patent database, official publication.
[2] EPO patent information reports on osteoarthritis compositions.
[3] Russian pharmaceutical patent landscape reports (2022).
[4] International Patent Application and Patent Publication Data.
